Evidence map›Paper›PMID 38811792›Full record

ArticleNature structural & molecular biology2024

MYC phase separation selectively modulates the transcriptome.

Junjiao Yang, Chan-I Chung, Jessica Koach, Hongjiang Liu, Ambuja Navalkar, Hao He, Zhimin Ma, Qian Zhao, Xiaoyu Yang, Liang He and 4 more

Erratum issuedAbstract read
In one paragraph

Article in Nature structural & molecular biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Targeting MYC-Driven Cancers: From Oncogenic Addiction to Therapeutic Vulnerability.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Junjiao Yang *Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-4844-2492
Chan-I Chung *Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
Jessica KoachDepartments of Neurology, Neurological Surgery, Pediatrics, and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
Hongjiang LiuInstitute for Human Genetics, Departments of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-6600-642X
Ambuja NavalkarDepartment of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Hao HeDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
Zhimin MaDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
Qian ZhaoDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
Xiaoyu YangInstitute for Human Genetics, Departments of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Liang HeDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
Tanja MittagDepartment of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-1827-3811
Yin ShenInstitute for Human Genetics, Departments of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-9901-5613
William A WeissDepartments of Neurology, Neurological Surgery, Pediatrics, and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-2230-9132
Xiaokun ShuDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA. xiaokun.shu@ucsf.edu.ORCID http://orcid.org/0000-0001-9248-7095

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kate Taylor Shumate · 1999 to 2026
$209.7M
Tumor microenvironment-dependent therapy resistanceP01CA217959 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI JOHN M MARIS · 2017 to 2026
$20.7M
Modulation and functional characterization of protein condensation in chromatin organizationU01DK127421 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HUANG, BO, NARLIKAR, GEETA J · 2020 to 2024
$5.4M
Integrating targeted and immunotherapy to treat genetically heterogeneous cancersU01CA217864 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BALMAIN, ALLAN, KRUMMEL, MATTHEW F · 2017 to 2021
$5.1M
EQUIPMENT for Designing a new class of fluorescent reporters for imaging dynamic cell signaling in live animalsR35GM131766 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHU, XIAOKUN · 2019 to 2025
$4.0M
Charting the 3D epigenome in human brain development and diseasesU01DA052713 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRIEGSTEIN, ARNOLD, SHEN, YIN · 2020 to 2024
$3.4M
Imaging and manipulating oncoprotein phase separation and compartmentalizationR01CA258327 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHU, XIAOKUN · 2021 to 2025
$2.1M
Dissecting functional roles of MeCP2 condensates in neurons with chemogenetic toolsR21DA056293 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHEN, YIN · 2022 to 2023
$444k
NCI NIH HHS P01 CA217959NCI NIH HHS P30 CA082103NCI NIH HHS R01 CA258327NCI NIH HHS U01 CA217864NIDA NIH HHS R21 DA056293NIDA NIH HHS U01 DA052713NIDDK NIH HHS U01 DK127421NIGMS NIH HHS R35 GM131766
6 · The paper itself

Abstract

Dysregulation and enhanced expression of MYC transcription factors (TFs) including MYC and MYCN contribute to the majority of human cancers. For example, MYCN is amplified up to several hundredfold in high-risk neuroblastoma. The resulting overexpression of N-myc aberrantly activates genes that are not activated at low N-myc levels and drives cell proliferation. Whether increasing N-myc levels simply mediates binding to lower-affinity binding sites in the genome or fundamentally changes the activation process remains unclear. One such activation mechanism that could become important above threshold levels of N-myc is the formation of aberrant transcriptional condensates through phase separation. Phase separation has recently been linked to transcriptional regulation, but the extent to which it contributes to gene activation remains an open question. Here we characterized the phase behavior of N-myc and showed that it can form dynamic condensates that have transcriptional hallmarks. We tested the role of phase separation in N-myc-regulated transcription by using a chemogenetic tool that allowed us to compare non-phase-separated and phase-separated conditions at equivalent N-myc levels, both of which showed a strong impact on gene expression compared to no N-myc expression. Interestingly, we discovered that only a small percentage (<3%) of N-myc-regulated genes is further modulated by phase separation but that these events include the activation of key oncogenes and the repression of tumor suppressors. Indeed, phase separation increases cell proliferation, corroborating the biological effects of the transcriptional changes. However, our results also show that >97% of N-myc-regulated genes are not affected by N-myc phase separation, demonstrating that soluble complexes of TFs with the transcriptional machinery are sufficient to activate transcription.

Indexed as

TranscriptomeCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansNeuroblastomaN-Myc Proto-Oncogene ProteinPhase SeparationProto-Oncogene Proteins c-mycMYCN protein, humanMYC protein, humanN-Myc Proto-Oncogene ProteinProto-Oncogene Proteins c-myc

Identifiers

PMID38811792
PMCPMC11479839

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.